Motavizumab

Motavizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target RSV glycoprotein F
Clinical data
Trade names Numax
Routes of
administration		 i.v.
ATC code J06BB17 (WHO)
Pharmacokinetic data
Protein binding None
Identifiers
CAS Number 677010-34-3 N
ChemSpider none
UNII 50Y163LK8Q YesY
KEGG D06621 YesY
Chemical and physical data
Formula C6476H10014N1706O2008S48
Molar mass Approximately 148 kg/mol
 NYesY (what is this?)  (verify)

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.[1]

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[2]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[3]

References

  1. ↑ ClinicalTrials.gov
  2. ↑ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
  3. ↑ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.


This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.